PUT/MODERNA/150/0.1/17.01.25 | Market Closed - BOERSE MUENCHEN 14:26:03 2024-06-28 EDT | ||
| 3.47 EUR | +2.36% |
|
| Current month | +45.80% | ||
| 1 month | +66.03% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
| Date | Price | Change |
|---|---|---|
| 24-06-28 | 3.47 | +2.36% |
| 24-06-27 | 3.39 | +9.00% |
| 24-06-26 | 3.11 | +22.44% |
| 24-06-25 | 2.54 | +0.40% |
| 24-06-24 | 2.53 | -5.24% |
Real-time BOERSE MUENCHEN
Last update June 28, 2024 at 02:26 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | MODERNA, INC. |
| Issuer | Goldman Sachs |
| WKN | GQ4DBD |
| ISIN | DE000GQ4DBD1 |
| Date issued | 2023-09-04 |
| Strike | 150 $ |
| Maturity | 2025-01-17 (201 Days) |
| Parity | 10 : 1 |
| Emission price | 4.27 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 7.652 € |
|---|---|
| Lowest since issue | 1.57 € |
| Spread | 0.07 € |
| Spread % | 1.96% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
118.8
USD
Average target price
145.9
USD
Spread / Average Target
+22.82%
- Stock Market
- Warrants
- Warrant
